Renal cell carcinoma (RCC) is responsible for up to 85% of kidney cancers, and over the past 12 years, RCC treatment has transitioned from a nonspecific immune treatment to a novel immunotherapy, namely vascular endothelial growth factor (VEGF) targeted therapy [76,77]. This evidence concerns the gene VEGFA and renal cell carcinoma.